AKR1C3 inhibitor CRT0083914 Small Molecule (Tool Compound)
Invented by Dr Laurent Rigoreau at Cancer Research Horizons
AKR1C3 inhibitor CRT0093964 Small Molecule (Tool Compound)
Invented by Dr Laurent Rigoreau from Cancer Research Horizons
Invented at Cancer Research Horizons
- Datasheet
- References (2)
- Inventor Info
Info
| Catalogue Number | 151880 |
| Antigen/Gene or Protein Targets | Type 5 17-β-Hydroxysteroid Dehydrogenase (AKR1C3) |
| Type | Inhibitor |
| Relevance | CRT0093964 is a highly potent and selective inhibitor of the Type 5 17-β-Hydroxysteroid Dehydrogenase (AKR1C3). |
| On Target IC50 | IC50 = 88 nM |
| Selectivity | Displays >100-fold selectivity against AKR1C1, AKR1C2 and AKR1C4. Does not display any COX (cyclooxygenase) inhibition at 10 µM in whole blood assay. |
| Molecular Formula | C15H20CIN3O2 |
| lUPAC | 4-(4-Chloro-phenyl)-piperazin-1-yl]-morpholin-4-yl-methanone |
| Molecular Weight (g/mol) | 309.79 |
| Research Area | Cell Signaling & Signal Transduction, Metabolism, Neurobiology |
| Notes | Referred to as A9 in Khanim et al., 2014. |
References: 2 entries
Khanim et al. 2014. Br J Cancer. 110(6):1506-16. PMID: 24569460.
Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Europe PMC ID: 24569460
Add a reference
References: 2 entries
Khanim et al. 2014. Br J Cancer. 110(6):1506-16. PMID: 24569460.
Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Add a reference
